Italia markets close in 6 hours 42 minutes
FTSE MIB
34.641,78 +302,46 (+0,88%) Dow Jones
39.387,76 +331,36 (+0,85%) Nasdaq
16.346,26 +43,46 (+0,27%) Nikkei 225
38.229,11 +155,13 (+0,41%) Petrolio
79,54 +0,28 (+0,35%) Bitcoin EUR
58.357,26 +1.431,90 (+2,52%)
NVCR May 2024 12.500 call
OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
In data: 03:20PM EDT. Mercato aperto.
| Chiusura precedente | 3,0000 |
| Aperto | 3,9000 |
| Denaro | 0,0000 |
| Lettera | 0,0000 |
| Prezzo d'esercizio | 12,50 |
| Scadenza | 2024-05-17 |
| Min-Max giorno | 3,0000 - 3,9000 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | N/D |
GlobeNewswireZai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with no added systemic toxicities Tumor Treating Fields therapy together with immune checkpoint inhibitors resulted in an unprecedented 8-month improvement in median overall survival LUNAR is the first phase 3 clinical trial in more than seven years to show a significant extension in overall survival in
© 2024 Yahoo. Tutti i diritti riservati.